Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Allorion Out-Licenses ex-China Rights for CDK2 Inhibitor to Avenzo in $1 Billion Deal

publication date: Jan 4, 2024

Allorion Therapeutics, a Boston-Guangzhou company, has out-licensed global rights (ex-China) for AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor, to Avenzo Therapeutics, a San Diego clinical-stage biotech. Allorion will also receive an exclusive option for an additional preclinical Avenzo program, which is expected to be ready for an IND submission in early 2025. Allorion will receive an upfront payment of $40 million and be eligible to receive milestone payments that could total more than $1 billion for the two candidates. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital